Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
According to results from the phase 2 TBCRC 056 trial, neoadjuvant niraparib plus dostarlimab demonstrated clinically meaningful pathologic complete response activity among patients with germline BRCA1/2-mutated triple-negative breast cancer.
According to results from the phase 2 TBCRC 056 trial, neoadjuvant niraparib plus dostarlimab demonstrated clinically meaningful pathologic complete response activity among patients with germline BRCA1/2-mutated triple-negative breast cancer.
Results from the phase 3 FABULOUS trial demonstrated that the addition of apatinib to fuzuloparib significantly improved progression-free survival compared with fuzuloparib monotherapy or standard chemotherapy among patients with...
Results from the phase 3 FABULOUS trial demonstrated that the addition of apatinib to fuzuloparib significantly improved progression-free survival compared with fuzuloparib monotherapy or standard chemotherapy among patients with...
Sacituzumab govitecan prolongs progression-free survival vs standard chemotherapy among previously untreated patients with locally advanced, unresectable or metastatic triple-negative breast cancer unable to undergo PD-1/PD-L1 inhibition,...
Sacituzumab govitecan prolongs progression-free survival vs standard chemotherapy among previously untreated patients with locally advanced, unresectable or metastatic triple-negative breast cancer unable to undergo PD-1/PD-L1 inhibition,...
Results from the phase 2 AMALEE trial show that a 400 mg starting dose of ribociclib, combined with a nonsteroidal aromatase inhibitor, reduced dose-dependent adverse events while maintaining efficacy vs the standard dose in HR-positive,...
Results from the phase 2 AMALEE trial show that a 400 mg starting dose of ribociclib, combined with a nonsteroidal aromatase inhibitor, reduced dose-dependent adverse events while maintaining efficacy vs the standard dose in HR-positive,...
Primary analysis results from the phase 3 CULMINATE-2 trial show that adding culmerciclib to fulvestrant significantly improves outcomes among previously untreated patients with HR-positive, HER2-negative locally advanced or metastatic breast...
Primary analysis results from the phase 3 CULMINATE-2 trial show that adding culmerciclib to fulvestrant significantly improves outcomes among previously untreated patients with HR-positive, HER2-negative locally advanced or metastatic breast...
Results from the phase 3 ASCENT-03 trial show that sacituzumab govitecan significantly improved efficacy and safety compared with standard chemotherapy among previously untreated patients with metastatic triple-negative breast cancer unable...
Results from the phase 3 ASCENT-03 trial show that sacituzumab govitecan significantly improved efficacy and safety compared with standard chemotherapy among previously untreated patients with metastatic triple-negative breast cancer unable...
According to results from the BEGONIA study, first-line datopotamab deruxtecan plus durvalumab demonstrated clinical promise among patients with advanced or metastatic triple-negative breast cancer.
According to results from the BEGONIA study, first-line datopotamab deruxtecan plus durvalumab demonstrated clinical promise among patients with advanced or metastatic triple-negative breast cancer.
Extended follow-up results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment continued to prolong survival among patients with HR-positive, HER2-negative early breast...
Extended follow-up results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment continued to prolong survival among patients with HR-positive, HER2-negative early breast...
A retrospective study found a positive correlation between MYB gene abnormalities and HER2 status among patients with mammary adenoid cystic carcinoma.
A retrospective study found a positive correlation between MYB gene abnormalities and HER2 status among patients with mammary adenoid cystic carcinoma.
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
According to the phase 2 TBCRC 056 trial of neoadjuvant niraparib plus dostarlimab in patients with germline BRCA1/2-mutated triple-negative breast cancer, which of the following best describes the observed antitumor and immunologic activity?
According to the phase 2 TBCRC 056 trial of neoadjuvant niraparib plus dostarlimab in patients with germline BRCA1/2-mutated triple-negative breast cancer, which of the following best describes the observed antitumor and immunologic activity?
Do you know the clinical impact of trastuzumab deruxtecan and sacituzumab govitecan across the HER2-negative subgroups of patients with HR-positive, HER2-negative metastatic breast cancer? Test your knowledge with our quick quiz!
Do you know the clinical impact of trastuzumab deruxtecan and sacituzumab govitecan across the HER2-negative subgroups of patients with HR-positive, HER2-negative metastatic breast cancer? Test your knowledge with our quick quiz!
Do you know what the intracranial activity of trastuzumab deruxtecan was among patients with HER2-low metastatic breast cancer with active brain metastases? Test your knowledge with our quiz!
Do you know what the intracranial activity of trastuzumab deruxtecan was among patients with HER2-low metastatic breast cancer with active brain metastases? Test your knowledge with our quiz!
True or False: Results from the ongoing phase 2 FUTURE-SUPER trial demonstrated that subtype-based therapy in the first-line setting significantly prolonged progression-free survival (PFS) among patients with previously untreated, metastatic...
True or False: Results from the ongoing phase 2 FUTURE-SUPER trial demonstrated that subtype-based therapy in the first-line setting significantly prolonged progression-free survival (PFS) among patients with previously untreated, metastatic...
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or false: Investigational agents such as pimicotinib and emactuzumab have shown encouraging activity in tenosynovial giant cell tumor (TGCT), with early data suggesting potentially higher response rates and improved safety profiles.
True or false: Investigational agents such as pimicotinib and emactuzumab have shown encouraging activity in tenosynovial giant cell tumor (TGCT), with early data suggesting potentially higher response rates and improved safety profiles.
True or false: Targeted therapies—including immune checkpoint inhibitors (ICIs) and mammalian target of rapamycin (mTOR) inhibitors—did not demonstrate improved survival in unselected glioblastoma populations, according to a systematic review...
True or false: Targeted therapies—including immune checkpoint inhibitors (ICIs) and mammalian target of rapamycin (mTOR) inhibitors—did not demonstrate improved survival in unselected glioblastoma populations, according to a systematic review...
True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...
True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or false: Eflornithine combined with lomustine significantly prolonged both progression-free and overall survival in patients with recurrent IDH-mutant, grade 3 astrocytoma following prior radiotherapy and temozolomide, compared with...
True or false: Eflornithine combined with lomustine significantly prolonged both progression-free and overall survival in patients with recurrent IDH-mutant, grade 3 astrocytoma following prior radiotherapy and temozolomide, compared with...
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
